Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

KalVista Pharmaceuticals (KALV) Gross Profit: 2014-2020

Historic Gross Profit for KalVista Pharmaceuticals (KALV) over the last 6 years, with Apr 2020 value amounting to $3.8 million.

  • KalVista Pharmaceuticals' Gross Profit rose 30.69% to $3.8 million in Q2 2020 from the same period last year, while for Apr 2020 it was $12.7 million, marking a year-over-year decrease of 21.31%. This contributed to the annual value of -$5.8 million for FY2025, which is 111.57% down from last year.
  • According to the latest figures from Q2 2020, KalVista Pharmaceuticals' Gross Profit is $3.8 million, which was up 142.49% from $1.6 million recorded in Q1 2020.
  • KalVista Pharmaceuticals' 5-year Gross Profit high stood at $5.6 million for Q4 2018, and its period low was $7,000 during Q1 2016.
  • For the 3-year period, KalVista Pharmaceuticals' Gross Profit averaged around $3.6 million, with its median value being $3.8 million (2018).
  • As far as peak fluctuations go, KalVista Pharmaceuticals' Gross Profit slumped by 90.15% in 2017, and later skyrocketed by 4,145.61% in 2018.
  • KalVista Pharmaceuticals' Gross Profit (Quarterly) stood at $197,000 in 2016, then spiked by 472.08% to $1.1 million in 2017, then surged by 396.18% to $5.6 million in 2018, then declined by 29.90% to $3.9 million in 2019, then soared by 30.69% to $3.8 million in 2020.
  • Its Gross Profit stands at $3.8 million for Q2 2020, versus $1.6 million for Q1 2020 and $3.9 million for Q4 2019.